Seeking Alpha
01 Jul 2026, 15:05 UTC · 3h ago
TransMedics: The Margins Must Recover
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
01 Jul 2026, 15:05 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
TransMedics' Q1 gross margin fell to 58.2% and adjusted EPS dropped to $0.30. — Direct evidence of margin pressure and earnings decline typically triggers short-term sell-offs in growth stocks.
-0.60Q1 revenue grew 21% to $173.9M. — Consistent double-digit top-line growth supports the long-term growth thesis despite short-term profit dips.
+0.40The company is building an integrated transplantation network to establish long-term market dominance. — The creation of a competitive moat suggests sustainable future pricing power and market share.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The article maintains a Buy rating and emphasizes a strong long-term growth thesis and moat despite short-term margin pressure.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Business Wire
25m ago
